Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol
The International Journal of Tuberculosis and Lung Disease · 2024
DOI: 10.5588/ijtld.23.0303 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2024. Verfasst von A Savinkina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Modeling Unit, and the, Epidemiology of Microbial Diseases Department, Yale School of Public Health, New Haven, CT, USA. Hauptthemen laut MEDLINE: Isoniazid, Antitubercular Agents, Latent Tuberculosis, HIV Infections. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDA NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
BACKGROUND
WHO guidance to defer isoniazid preventive therapy (IPT) among those with regular alcohol use because of hepatotoxicity concerns may exclude many people living with HIV (PLWH) at high TB risk in these settings.
OBJECTIVE
To evaluate hepatotoxicity during TB preventive therapy (TPT) in PLWH who report alcohol use in Uganda over 10 years.
METHODS
We developed a Markov model of latent TB infection, isoniazid preventive therapy (IPT - a type of TPT), and TB disease using data from the Alcohol Drinkers’ Exposure to Preventive Therapy for TB (ADEPTT) study. We modeled several treatment scenarios, including no IPT, IPT with liver enzyme monitoring (AST/ALT) during treatment, and IPT with pre-screening using the tuberculin skin test (TST).
RESULTS
The no IPT scenario had 230 TB deaths/100,000 population over 10 years, which is more than that seen in any IPT scenario. IPT, even with no monitoring, was preferred over no IPT when population TB disease incidence was >50 in 100,000.
CONCLUSIONS
For PLWH who report alcohol use in high TB burden settings, IPT should be offered, ideally with regular AST/ALT monitoring. However, even if regular monitoring is not possible, IPT is still preferable to no IPT in almost every modeled scenario.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Public Health Modeling Unit, and the, Epidemiology of Microbial Diseases Department, Yale School of Public Health, New Haven, CT, USA.
- Mbarara Regional Referral Hospital, Mbarara, Mbarara University of Science and Technology, Mbarara, Uganda.
- Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, and the, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA.
- Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, and the.
- Mbarara University of Science and Technology, Mbarara, Uganda.
- Boston University School of Public Health, Boston, MA, Boston University School of Medicine, Boston, MA, Boston Medical Center, Boston, MA, USA.
Förderung
- NIAID NIH HHS
- NIDA NIH HHS
- NIAAA NIH HHS
Zitieren
APA
Savinkina, A., Muyindike, W., Hahn, J. A., Emenyonu, N. I., Fatch, R., Ngabirano, C., Adong, J., Jacobson, K. R., & Linas, B. P. (2024). Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.23.0303
Vancouver
Savinkina A, Muyindike W, Hahn JA, Emenyonu NI, Fatch R, Ngabirano C, et al. Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol. The International Journal of Tuberculosis and Lung Disease. 2024. doi:10.5588/ijtld.23.0303
BibTeX
@article{Savinkina2024,
author = {Savinkina, A and Muyindike, W and Hahn, J A and Emenyonu, N I and Fatch, R and Ngabirano, C and Adong, J and Jacobson, K R and Linas, B P},
title = {Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2024},
doi = {10.5588/ijtld.23.0303}
}
EUVIMED